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Abstract.
Background: Miller Fisher syndrome is a regional variant of Guillain-Barre syndrome with a characteristic clinical triad of
ophthalmoplegia, areflexia and ataxia and occasionally distal limb sensory loss. 90% of patients have associated antibodies to
the GQ1b ganglioside. The pathophysiology of antibody-mediated peripheral nerve impairment remains uncertain. This report
includes the first description of a peripheral sensory nerve biopsy in Miller Fisher syndrome.
Results: A single case report is described of a 46 year old woman who presented with 2 weeks of distal glove and stocking
sensory loss to both deep and superficial sensory modalities, areflexia and weight loss. This was followed by rapid onset of
ataxia, ophthalmoplegia, and bulbar impairment. Peripheral neurophysiology showed reduced sensory nerve amplitudes with
preserved conduction velocities in keeping with an axonal pattern of impairment. Clinical concerns of a systemic inflammatory
disorder led to a diagnostic peripheral nerve biopsy from the sensory branch of the radial nerve. However she subsequently made
a complete recovery over 5 weeks. Combinatorial glycoarrays confirmed restricted serum binding for GQ1b in acute serum
which later resolved in a convalescent sample. The nerve biopsy showed lengthening of nodes of Ranvier, myelin splitting and
macrophage internodal axonal invasion without any features of demyelination.
Conclusions: The pathological features were strikingly similar to those found in acute motor axonal neuropathy and indicate
the region of the node of Ranvier to be a primary focus of GQ1b induced damage in Miller Fisher syndrome, at least in this
particular overlap syndrome with prominent sensory nerve involvement.
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ABBREVIATIONS
AMAN Acute motor axonal neuropathy
AMSAN Acute motor-sensory axonal neuropathy
ASAN Acute sensory ataxic neuropathy
GBS Guillain-Barre´ syndrome
MFS Miller Fisher syndrome
MRI Magnetic resonance imaging
CT Computed tomography
PET-CT Positron emission tomography
- computed tomography
SAP Sensory nerve amplitude
A 46 year old Caucasian female sales assistant was
admitted to our unit on the 7th March 2011 with a two
week history of symmetric numbness and paraesthe-
siae initially of both hands, then her legs, and four
days of rapidly progressive unsteadiness, diplopia,
dysarthria and dysphagia. Her sensory symptoms were
preceded by flu-like symptoms with lethargy and
fever one week earlier. She gave a history of unex-
plained weight loss of several months duration. She
had stopped smoking 3 months earlier but otherwise
past medical and family history were unremarkable.
On examination she was alert and orientated. She
had an ataxic gait, without Rombergism. Pupils were
equal and reactive to light but not to accommodation.
She had a lid retraction without ptosis and a com-
plex ophthalmoplegia comprising restricted upgaze,
normal downgaze, and markedly restricted horizontal
gaze bilaterally. Nasal speech was noted with reduced
elevation of the soft palate and nasal regurgitation.
There was no facial weakness and tone and power of all
four limbs were normal. She had an intention tremor
with dysmetria in both upper limbs. She was areflexic
throughout with flexor plantar responses. Sensation to
pinprick was reduced to above the wrists and knees
bilaterally. Vibration sense was absent below the hips
but proprioception was intact. There was no evidence
of autonomic instability. General physical examina-
tion, apart from being underweight with a body mass
index of 16, was unremarkable.
Her complete blood cell count, vitamin B12, ery-
throcyte sedimentation rate, renal, liver and thyroid
function were all normal. Anti-nuclear antibody,
acetylcholine receptor antibody, voltage-gated cal-
cium channel antibody and borreliosis serology
were negative. Anti-GQ1b antibodies in serum col-
lected on admission were positive on enzyme-linked
immunosorbent assay (ELISA) at 1/1200 (normal
range <1/500) conducted according to standard pro-
Fig. 1. Combinatorial glycoarray demonstrating restricted anti-
GQ1b IgG reactivity of patient. Combinatorial glycoarrays are
designed to identity antibody reactivity to single glycolipids (dupli-
cated in top row and left-hand row) and 1:1 glycolipid complexes
(remainder of grid). A line of symmetry runs top left to bottom right,
representing analysis in duplicate. In the acute phase serum, strong
reactivity to GQ1b is seen that is not substantially enhanced or inhib-
ited when in complex with other glycolipids. In the convalescent
serum, anti-GQ1b antibody activity is no longer detectable, except
for a low antibody signal for the complex of GQ1b with GD1a.
tocols [1]. Combinatorial glycoarrays allow detection
of anti-glycolipid complex antibodies (conducted
as previously described [2]) and these glycolipid
immunoblots for the serum collected on admission
and for a convalescent sample taken 5 months later
are shown in Fig. 1. They demonstrate strong reactiv-
ity exclusively for GQ1b in the acute serum which is
absent in the convalescent serum.
Lumbar puncture on the day of admission showed
normal cerebrospinal fluid constituents including cell
count and protein. Peripheral neurophysiology on the
8th March showed normal motor nerve conduction
studies but reduced amplitudes in sensory nerve con-
duction studies with preserved conduction velocities
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Table 1
Serial sensory nerve conduction studies
Nerve tested Latency (msec) Amplitude (V) Conduction velocity (m/sec)
First study Second study First study Second study First study Second study
Radial digit I L 2.1 (<3.3) NR 2.9 (>4) NR 49 (>50) NR
Radial trunk L 2.2 (<2.7) 1.8 22 (>28) 11 52 (>50) 51
Median digit III L 3.3 (<3.0) NR 2.4 NR 41 NR
Median PW L 1.7 (<1.2) 1.5 15 (NA) 10 44 (>50) 53
Sural R 2.7 (<3.2) NR 5.5 (>5) NR 44 (>52) NR
NA, not applicable due to wide variation in population; NR, no response; PW, palm to wrist; R, right side; L, left side. First study performed
2 weeks after onset of symptoms, second study 3 weeks after onset of symptoms. In parentheses, cut-off value of normal range used in our
laboratory (derived from published values of mean ± 2SD, adjusted for age). Abnormal results highlighted in bold.
Fig. 2. Acute axonal degeneration of myelinated fibres. Transverse sections show axons that are either filled with amorphous material (white
arrows in A and B) or are shrunken in size and/or surrounded by clear spaces/oedema (white chevrons in A and B). Some axons are replaced by
macrophages (black arrow in B). Myelin ovoids containing myelin debris have formed following axon loss (black chevron in B). Focal loss of
small myelinated axons is noticeable in B compared to A. Semi-thin plastic section, thionine and basic fuchsin stain, bar = 27m.
(or mild reduction in conduction velocity commen-
surate with the loss of amplitude) in keeping with
a sensory nerve-restricted axonopathy rather than a
demyelinating process (Table 1). One week later, there
was further deterioration in sensory nerve action poten-
tials (SAPs) with loss of more distal nerve responses
(such as median digital response), whereas more prox-
imal sensory studies such as the median palm to wrist
were still present, although with reduced amplitudes,
in keeping with distal conduction block. MRI of the
brain and cervical spine were unremarkable.
A diagnostic biopsy of the right superficial sensory
branch of the radial nerve was performed on the 21st of
March 2011. There was a variable loss of large myeli-
nated fibres of mild extent in the majority of nerve
fascicles and of moderate degree in a few fascicles
with sparing of small myelinated fibres other than for
rare areas of focal loss. Higher magnification revealed
that scattered large myelinated fibres showed acute
stages of axonal degeneration whilst myelin sheaths
remained relatively intact with no signs of acute seg-
mental demyelination or onion bulbs (Figs. 2 and 3).
Both transverse and longitudinal sections revealed sev-
eral large myelinated fibres with lengthening of nodes
of Ranvier and myelin splitting at paranodes and at
Schmidt-Lanterman incisures through internodes and
macrophage invasion of the axonal space.
Five days after admission, her ophthalmoplegia and
ataxia continued to worsen and she was treated with
intravenous methylprednisolone 1gm for three days,
starting on the 12th March. Over the next two weeks her
condition initially stabilised and then rapidly improved
such that her dysarthria and dysphagia had resolved
and she had diplopia only at extremes of gaze, with
minimal reduction of abduction bilaterally. Sensory
abnormalities had partially improved at this time with
complete recovery over the following 3 weeks.
DISCUSSION
Miller Fisher syndrome (MFS) is a regional vari-
ant of Guillain-Barre´ syndrome (GBS). Antibodies
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Fig. 3. Disruption of nodes of Ranvier and paranodal region. Longitudinal sections of large myelinated fibres exhibiting lengthening of nodes of
Ranvier (white arrows in A and B; normal - black arrowhead in A) and myelin splitting at paranodes (black arrows in A and B). Compare with
normal width of nodes of Ranvier (black arrowhead in A). Remnants of a degenerating myelinated fibre with myelin debris lying in ovoids (white
arrowhead in B). There is no evidence of segmental demyelination. Semi-thin plastic section, thionine and basic fuchsin stain, bar = 37m.
to the GQ1b ganglioside are present in over 90%
of patients [3]. It has a characteristic clinical triad
of acute ophthalmoplegia, areflexia and ataxia with
variable additional features including sensory loss,
facial weakness and bulbar palsy [4]. Patients typi-
cally present acutely with a mean interval to nadir from
onset of 4 days [5]. In a recent series of 466 Japanese
patients, distal paraesthesiae were reported frequently
but uncommonly as a presenting complaint (14%) and
with superficial sensory loss (spinothalamic modali-
ties) on examination in only half of these [5]. In our
patient an acute sensory axonal neuropathy developed
2 weeks prior to the ophthalmoplegia, ataxia and bulbar
impairment. In conjunction with a history of weight
loss this atypical presentation raised concerns of an
underlying systemic inflammatory disorder and so to
diagnostic nerve biopsy. It was only with the subse-
quent rapid and complete recovery and the elevated
anti-GQ1b antibody titre that the diagnosis of a sen-
sory neuropathy as part of an extended MFS syndrome
was established.
Sub-types of GBS are classified on the basis of the
anatomical site of the predominant pathological mech-
anism leading to peripheral nerve impairment [4]. In
MFS the core clinical features result from disturbance
of function to the oculomotor cranial nerves causing
ophthalmoplegia and with ataxia and areflexia sec-
ondary to impairment of dorsal root ganglia and / or
muscle spindles. None of these structures is readily
accessible to either neurophysiological interrogation
or pathological study of biopsy material to clarify
the site of the anti-GQ1b antibody mediated nerve
damage. Motor neurophysiological studies are nor-
mal or near-normal in most patients in keeping with
the lack of substantial limb weakness. In a minority
of cases where there is significant superficial sen-
sory impairment, neurophysiological studies reveal
reduced sensory nerve amplitudes without demyeli-
nating features. The typical rapid clinical recovery
suggests that the sensory nerve impairment results
from non-demyelinating, reversible conduction failure
rather than axonal damage [6].
Reversible conduction failure was first recognised in
patients with acute motor axonal neuropathy (AMAN)
associated with antibodies to GM1 antibodies. It results
from interruption of the action potential propagation
at the nodes of Ranvier [7]. Immune-mediated damage
causes structural and functional disruption of ion chan-
nels and terminal myelin detachment at the paranode.
A similar mechanism has been invoked for a restricted
sensory ataxic variant with axonal neurophysiological
abnormalities (ASAN) and accompanying antibodies
to gangliosides including GQ1b and GD1b [8]. An
alternative terminology suggested for these axonal
GBS variants associated with conduction block is of
a “nodo-paranodopathy” [9].
The histological features observed in the sensory
nerve of our patient closely mimic those described
in AMAN where macrophage entry occurs via the
nodes of Ranvier and Schmidt-Lanterman incisures,
invading between the axon and the Schwann cell
axolemma and producing lengthening of the nodes
and myelin splitting which causes conduction fail-
ure. A paranodal distribution of GQ1b epitope has not
been studied in human sensory nerves but is found
in the extramedullary portion of oculomotor nerves
[10]. In vitro GQ1b-specific antibodies also bind both
at the nerve terminals contacting intrafusal fibres in
muscle spindles [11] and in the human dorsal root
ganglion [12] suggesting that sensory nerve impair-
ment in Miller Fisher syndrome results from damage
at multiple sites.
Our case is the first description of a peripheral
nerve biopsy in MFS as the clinical phenotype is
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often characteristic and the course usually self-limiting
and benign. Two previous post mortem reports on
patients considered to have MFS demonstrated patchy
but extensive segmental demyelination of peripheral
nerves but the poor clinical outcome in both these
cases would be highly unusual for MFS and anti-GQ1b
antibodies were not measured [13, 14].
In conclusion, our patient demonstrates that a simi-
lar pathophysiological process occurs in the peripheral
sensory nerves in GQ1b-restricted MFS as has been
reported in axonal GBS variants. This would support
the classification of MFS either as a regional vari-
ant of AMSAN or alternatively as a member of the
“nodo-paranodopathies”.
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